Highly Anticipated Alzheimer’s Trials Yield Disappointing Results for GLP-1 Drug

(MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday.
The company shared topline results from the 2-year…